Definitions

from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. A histone deacetylase inhibitor proposed as an anticancer drug

Etymologies

Sorry, no etymologies found.

Examples

  • "We believe Dr. Holzer will be an immediate value-added member of the Spectrum Pharmaceuticals commercial organization as we continue to grow the FUSILEV and ZEVALIN brands and prepare for the additions of apaziquone and belinostat over the next 12-18 months," said Rajesh C.

  • He will be primarily responsible for leading and managing Spectrum's cross-functional brand efforts for FUSILEV ┬« and ZEVALIN┬« as well as brand planning for apaziquone and belinostat, Spectrum's late-stage drugs in development.

  • The Company markets two oncology and hematology drugs, FUSILEV and ZEVALIN and has two drugs, apaziquone and belinostat, in late stage development along with a diversified pipeline of novel drug candidates.

  • If approved, we believe belinostat will add value to our existing hematology/oncology portfolio, increase our current sales efforts in hematology/oncology, and demonstrate our commitment to developing novel treatments for lymphoma.

  • Additionally, the National Cancer Institute is currently conducting several clinical trials of belinostat in a variety of hematological and solid tumors, both as monotherapy as well as combination therapy.

  • The Company markets two oncology drugs, FUSILEV and ZEVALIN and has two drugs, apaziquone and belinostat, in late stage development along with a diversified pipeline of novel drug candidates.

    Spectrum Pharmaceuticals to Develop Biosimilar Rituximab - Yahoo! Finance

  • The Company markets two oncology drugs, FUSILEV and ZEVALIN, and has two drugs, apaziquone and belinostat, in late stage development along with a diversified pipeline of novel drug candidates.

    Spectrum Pharmaceuticals Submits Supplemental New Drug Application (sNDA) for Ready-to-Use Formulation of FUSILEV® in Colorectal Cancer - Yahoo! Finance

  • The Company markets two oncology drugs, FUSILEV and ZEVALIN and has two drugs in late stage development, apaziquone and belinostat, along with a diverse pipeline.

    The Earth Times Online Newspaper

  • The Company markets two oncology drugs, FUSILEV and ZEVALIN and has two drugs, apaziquone and belinostat, in late stage development along with

    Business Wire Travel News

  • This included $17.5 million received in the first quarter for apaziquone out-licensing and milestone fees, and a one-time, upfront license fee of $30 million paid, also in the first quarter, for belinostat.

    Business Wire Travel News

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.